Perceptive Advisors LLC Position in Nxstage Medical INC (NXTM) Lowered as Stock Value Declined

December 14, 2017 - By Jan Rainey

Investors sentiment increased to 1.14 in 2017 Q2. Its up 0.10, from 1.04 in 2017Q1. It is positive, as 24 investors sold NXTM shares while 47 reduced holdings. 28 funds opened positions while 53 raised stakes. 58.75 million shares or 4.24% less from 61.35 million shares in 2017Q1 were reported. Endurant Cap Mgmt Ltd Partnership holds 0.77% in Nxstage Medical, Inc. (NASDAQ:NXTM) or 108,300 shares. Schwab Charles Invest Mgmt invested in 280,092 shares or 0.01% of the stock. Geode Capital Mngmt Limited Liability Company owns 0.01% invested in Nxstage Medical, Inc. (NASDAQ:NXTM) for 615,151 shares. Trexquant Investment Lp holds 17,387 shares or 0.12% of its portfolio. Aperio Grp Ltd Liability Corporation reported 8,133 shares. State Board Of Administration Of Florida Retirement Sys has invested 0% in Nxstage Medical, Inc. (NASDAQ:NXTM). Bnp Paribas Arbitrage Sa invested 0% of its portfolio in Nxstage Medical, Inc. (NASDAQ:NXTM). Natl Bank Of Mellon Corporation holds 0% or 587,996 shares in its portfolio. Fil Limited invested in 148,452 shares or 0.01% of the stock. Quantitative Systematic Strategies Ltd Liability Corporation reported 8,236 shares. Lombard Odier Asset Management (Usa) Corp invested in 123,281 shares. 190,406 are owned by Advisory. Parametric Port Associates Ltd Liability accumulated 61,104 shares. Solutions Limited Liability reported 0% in Nxstage Medical, Inc. (NASDAQ:NXTM). Nuveen Asset Mgmt Limited owns 136,174 shares.

Since June 15, 2017, it had 0 buys, and 11 insider sales for $1.60 million activity. On Wednesday, September 20 Swan Winifred L sold $95,445 worth of Nxstage Medical, Inc. (NASDAQ:NXTM) or 3,500 shares. Turk Joseph E Jr sold 24,000 shares worth $711,300.

Joseph Edelman decreased its stake in Nxstage Medical Inc (NXTM) by 14.45% based on its latest 2017Q2 regulatory filing with the SEC. Perceptive Advisors Llc sold 262,666 shares as the company’s stock declined 27.12% while stock markets rallied. The hedge fund run by Joseph Edelman held 1.56M shares of the health care company at the end of 2017Q2, valued at $39.00M, down from 1.82M at the end of the previous reported quarter. Perceptive Advisors Llc who had been investing in Nxstage Medical Inc for a number of months, seems to be less bullish one the $1.73 billion market cap company. The stock increased 0.66% or $0.17 during the last trading session, reaching $26.06. About 590,144 shares traded or 0.99% up from the average. Nxstage Medical, Inc. (NASDAQ:NXTM) has risen 21.18% since December 14, 2016 and is uptrending. It has outperformed by 4.48% the S&P500.

Perceptive Advisors Llc, which manages about $2.09 billion and $1.99B US Long portfolio, upped its stake in Antares Pharma Inc (NASDAQ:ATRS) by 1.35 million shares to 4.27 million shares, valued at $13.74 million in 2017Q2, according to the filing. It also increased its holding in Audentes Therapeutics Inc by 700,000 shares in the quarter, for a total of 707,500 shares, and has risen its stake in Radius Health Inc (NASDAQ:RDUS).

More notable recent Nxstage Medical, Inc. (NASDAQ:NXTM) news were published by: Bizjournals.com which released: “Fresenius to buy Lawrence-based ​NxStage Medical for $2B” on August 07, 2017, also Fool.com with their article: “Why NxStage Medical, Inc. Got Hammered Today” published on May 09, 2017, Prnewswire.com published: “NxStage Celebrates Over 5000 Home Hemodialysis Patients Receiving Kidney …” on December 11, 2017. More interesting news about Nxstage Medical, Inc. (NASDAQ:NXTM) were released by: Prnewswire.com and their article: “Nx2me Connected Health® Improves Home Hemodialysis Retention” published on December 07, 2017 as well as Prnewswire.com‘s news article titled: “Breakfast Technical Briefing on Medical Equipment Stocks — Hologic, Nxstage …” with publication date: November 16, 2017.

Nxstage Medical, Inc. (NASDAQ:NXTM) Ratings Coverage

Among 9 analysts covering NxStage Medical (NASDAQ:NXTM), 2 have Buy rating, 1 Sell and 6 Hold. Therefore 22% are positive. NxStage Medical had 18 analyst reports since November 4, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Tuesday, August 8 by Jefferies. On Monday, August 7 the stock rating was downgraded by Canaccord Genuity to “Hold”. The company was maintained on Tuesday, October 10 by Jefferies. Piper Jaffray reinitiated the stock with “Overweight” rating in Thursday, March 31 report. BTIG Research maintained it with “Buy” rating and $2700 target in Tuesday, June 6 report. BTIG Research downgraded the stock to “Neutral” rating in Friday, August 11 report. Canaccord Genuity maintained Nxstage Medical, Inc. (NASDAQ:NXTM) rating on Monday, September 11. Canaccord Genuity has “Hold” rating and $30.0 target. The firm earned “Hold” rating on Monday, August 7 by Craig Hallum. Canaccord Genuity maintained it with “Hold” rating and $30.0 target in Monday, October 16 report. On Monday, August 7 the stock rating was maintained by Northland Capital with “Hold”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.